|
Launch of Citracal F/D
2006.01.06
|
|---|
|
Daehan New Pharm Co., Ltd. Launches "Citracal F/D Tablets" Improved Calcium Bioavailability... Minimizes Side Effects Such as Gastrointestinal Disorders
Daehan New Pharm Co., Ltd. (CEO Park Myung-rae) has released ETC-type "Citracal F Tablets" and OTC-type "Citracal D Tablets," calcium supplements combining calcium citrate and vitamin D3.
Citracal F/D Tablets, combining calcium citrate and vitamin D3, have improved absorption rate and calcium bioavailability by over 30% compared to conventional calcium carbonate or oyster shell powder. Unlike calcium carbonate supplements, they do not produce gas in the intestines, minimizing side effects such as gastrointestinal discomfort, constipation, and kidney stone formation. Particularly, Citracal F Tablets are covered by insurance and improve patient adherence with a once-daily dosage.
Daehan New Pharm Co., Ltd. aims to expand sales by dual marketing strategies using Citracal F Tablets for ETC prescriptions and Citracal D Tablets for OTC pharmacy sales. |


Home